# DefEYE Raises $12M Series Seed with Celularity Partnership and ExSight Ventures Investment

> financing · REPORTED · 2025-10-30

DefEYE closed a $12 million Series Seed Preferred Equity round in late 2025, anchored by a strategic partnership and in-kind investment from Celularity, which also granted DefEYE an exclusive license to its BIOVANCE amnion-derived ocular allografts; ExSight Ventures separately made an additional investment to accelerate commercialization.

About DefEYE, Inc.: DefEYE, Inc. is a Sarasota, Florida-based ophthalmic biologics company that develops and commercializes decellularized placental tissue solutions, including BIOVANCE 3L Ocular, for the treatment of ocular surface disease and surgical interventions such as pterygium surgery.

- Company: DefEYE
- Sector: medical devices
- Primary source: https://www.barchart.com/story/news/35791447/celularity-and-defeye-inc-partner-to-advance-growth-of-regenerative-therapies-in-eye-care

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.